Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
UNLABELLED: (11)C-Pittsburgh compound B (PiB) marks Abeta amyloidosis, a key pathogenetic process in Alzheimer disease (AD). The use of (11)C-PiB is limited to centers with a cyclotron. Development of the (18)F-labeled thioflavin derivative of PiB, (18)F-flutemetamol, could hugely increase the avail...
Автори: | Nelissen, N, Van Laere, K, Thurfjell, L, Owenius, R, Vandenbulcke, M, Koole, M, Bormans, G, Brooks, D, Vandenberghe, R |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
2009
|
Схожі ресурси
-
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
за авторством: Vandenberghe, R, та інші
Опубліковано: (2010) -
Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
за авторством: Val J. Lowe, та інші
Опубліковано: (2017-01-01) -
Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
за авторством: Vandenberghe, R, та інші
Опубліковано: (2013) -
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.
за авторством: Koole, M, та інші
Опубліковано: (2009) -
Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
за авторством: Emma S. Luckett, та інші
Опубліковано: (2023-01-01)